LAVA Therapeutics NV Cashflow Statement

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
Loss before income tax
Depreciation and amortization of non-current assets
Foreign currency exchange (gain) loss, net
Depreciation of right-of-use assets
Share-based compensation expense
Income tax expense
Amortization of premium on investments
Receivables and other
VAT receivable
Other assets
Prepaid expenses and other assets
Trade accounts payable and other
Deferred offering & financing costs
Deferred revenue
License liabilities
Other liabilities
Net cash (used in) provided by operating activities
Purchases of property and equipment
Purchases of investments
Maturities of investments
Net cash (used in) provided by investing activities
Proceeds from option exercises
Proceeds from common shares from initial public offering, net
Proceeds from Series C financing, net
Payment of Series A preferred and common shares repurchased
Proceeds from borrowings
Payment of principal portion of lease liabilities
Net cash (used in) provided by financing activities
Net (decrease) increase in cash and cash equivalents
Issuance of common shares to VUmc in lieu of payment for license liabilities
Interest received, classified as operating activities
Interest paid, classified as operating activities
Cash flows from operating activities:
Net loss
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation and amortization
Non-cash operating lease expense
Foreign currency exchange gain loss, net
Share-based compensation expense
Accrued interest on borrowings
Amortization of premium on short-term investments
Deferred income taxes
Changes in operating assets and liabilities:
Prepaid expenses and other current assets
Other non-current assets
Accounts payable
Accrued expenses and other current liabilities
Operating lease liabilities
License liabilities
Net cash used in operating activities
Cash flows from investing activities:
Purchases of property and equipment
Proceeds from sale of property and equipment
Purchases of investments
Maturities of investments
Net cash generated from (used in) investing activities
Cash flows from financing activities:
Proceeds from option exercises
Repayment of borrowings
Net cash used in financing activities
Net decrease in cash and cash equivalents
Cash and cash equivalents at beginning of year
Effects of exchange rate changes
Cash and cash equivalents at end of year
Supplemental disclosure of cash flow information:
Cash paid for income taxes
Operating right-of-use assets obtained in exchange for operating lease liabilities
Adjustment to operating lease right-of-use assets from lease modification

Comments